Progress of Chimeric Antigen Receptor Gene Modified-T Cell Immunotherapy for Thoracic Malignancies
10.3971/j.issn.1000-8578.2023.23.0144
- VernacularTitle:CAR-T细胞免疫在胸部恶性肿瘤中的研究进展
- Author:
Fukun CHEN
1
;
Nana CHEN
;
Zhiyong DENG
;
Juan LYU
;
Wenjing QIN
;
Jialun ZHU
Author Information
1. Department of Nuclear Medicine, Yunnan Cancer Hospital, the Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China
- Publication Type:Research Article
- Keywords:
Thoracic malignancies;
CAR-T;
Immunotherapy;
Antigen target;
Solid tumor
- From:
Cancer Research on Prevention and Treatment
2023;50(10):1010-1014
- CountryChina
- Language:Chinese
-
Abstract:
With a deepened understanding of the pathophysiology and pathogenesis of thoracic malignancies, the treatment has been transited from traditional treatment on the basis of surgery, radiotherapy, and chemotherapy to individualized and precise targeted therapy and immunotherapy. As an antitumor immunotherapy, chimeric antigen receptor gene-modified T (CAR-T) cells have been approved by the FDA for the treatment of hematological malignancies in five CAR-T products. They have also achieved good therapeutic effects in solid tumors. However, significant challenges remain in the clinical application of CAR-T cell immunotherapy in thoracic malignancies. In this review, the latest research progress of CAR-T cell immunotherapy in the treatment of thoracic malignancies were summarized, including the basic characteristics of CAR-T cells, the popular target antigens, and the existing problems and challenges, to provide new ideas and strategies for clinical immunotherapy of thoracic malignancies.
